BioCentury
ARTICLE | Clinical News

MG98: BBG plans to start next quarter a Phase I study of a continuous infusion of MG98 over 2 weeks to treat solid tumors in an undisclosed number of patients.

July 15, 2002 7:00 AM UTC

British Biotech plc (LSE:BBG; BBIOY), Oxford, U.K. MethylGene Inc., Montreal, Quebec MGI Pharma Inc. (MOGN), Minneapolis, Minn. Business: Cancer Product: MG98 Therapeutic category: Antisense Descrip...